19 Apr 2021 07:00
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
National Framework contract award for Covid-19 testing products and services
Yourgene successful in UK-wide National Microbiology Framework (Lot 1)
Manchester, UK - 19 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded a Framework Agreement under Public Health England's ("PHE") National Microbiology Framework for Lot 1 (Diagnostic Goods and Services) of the four-lot tender for its Clarigene® SARS-CoV-2 assay and Manchester-based COVID testing service.
PHE's National Microbiology Framework is appointing suppliers to framework agreements for four lots. Lot 1 is the first to be announced and covers the supply of in-vitro diagnostic medical devices and associated services, including for the Company's Clarigene® SARS-CoV-2 PCR assay and the associated clinical laboratory testing services delivered through Yourgene Genomic Services. The term of the Framework Agreement for Lot 1 (and for each subsequent lot, if awarded) is for an initial two years with options to extend by up to a further two years. Lot 1 is a £3bn tender to be satisfied by multiple successful bidders.
Under the National Microbiology Framework, participating public health authorities across the United Kingdom can use call-off contracts to procure goods and testing services from Yourgene under such lots as it is in receipt of a Framework Agreement, but there is no guarantee that such contracts will be forthcoming, nor as to the quantum of any potential call-off contracts may which arise.
Lyn Rees, CEO of Yourgene commented:
"We welcome the opportunity to work with PHE and its sister organisations across the NHS, DHSC and in Wales, Scotland and Northern Ireland to offer our Clarigene® SARS-CoV-2 PCR assay, and our accredited lab testing services, to contain Covid-19 in the near-term and to participate in putting in place a robust testing infrastructure post-pandemic. Yourgene considers that the successful framework award, for which there was a competitive tender process, lends significant credibility to the Clarigene® product and to the Company's COVID testing services. More broadly, we expect the award to support business development outside the scope of this agreement with a growing network of commercial partners, addressing privately funded testing in healthcare and workplace settings."
This announcement contains inside information for the purposes of UK Market Abuse Regulation . The Directors of the Company take responsibility for this announcement.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com | |||
Barry Hextall, Chief Financial Officer |
| |||
Joanne Cross, Director of Marketing |
| |||
|
| |||
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | |||
Liam Murray / James Caithie / Ludovico Lazzaretti |
| |||
N+1 Singer (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 | |||
Aubrey Powell / Tom Salvesen / George Tzimas |
| |||
|
| |||
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | |||
Nicholas Moore / Matthew Blawat / Ben Maddison |
| |||
|
| |||
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | |||
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / Mob: 07584 391 303 | |||
|
|
|
| |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.